Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02970305 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)
A Phase 2 study, sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 403
- Enrollment target
NCT02970305 is a Phase 2 study that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 403 participants.
The verdict
NCT02970305, a Phase 2 study, has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 403 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of the negative symptoms of schizophrenia
Interventions
- DRUG Placebo
- DRUG Pimavanserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 403 participants |
| Start Date | 2016-11-04 |
| Est. Completion | 2019-10-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02970305
The ClinicalTrials.gov registry entry for NCT02970305 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 403 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02970305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02970305 about?
NCT02970305 is a clinical study titled "Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)". To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of the negative symptoms of schizophrenia
What is the current status of trial NCT02970305?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 403 participants. The study started on 2016-11-04. Estimated completion is 2019-10-28.
What interventions are being tested in trial NCT02970305?
The interventions under investigation include: Placebo (DRUG), Pimavanserin (DRUG).
Who is sponsoring clinical trial NCT02970305?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.